Equities

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Actions
  • Price (EUR)9.16
  • Today's Change-0.738 / -7.46%
  • Shares traded500.00
  • 1 Year change+145.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments280472504
Total Receivables, Net0.15----
Total Inventory10----
Prepaid expenses177.273.55
Other current assets, total------
Total current assets308479508
Property, plant & equipment, net177178170
Goodwill, net------
Intangibles, net229----
Long term investments--092
Note receivable - long term------
Other long term assets0.270.191.78
Total assets780664777
LIABILITIES
Accounts payable332727
Accrued expenses776562
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities1109189
Total long term debt1.001.001.00
Total debt1.001.001.00
Deferred income tax17----
Minority interest------
Other liabilities, total677265
Total liabilities196164156
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital2,5942,0691,795
Retained earnings (accumulated deficit)(2012)(1568)(1172)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total2.53(0.9)(0.6)
Total equity585500622
Total liabilities & shareholders' equity780664777
Total common shares outstanding256188157
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.